NEW YORK, Jan 9, 2026, 12:43 EST — Regular session
Regencell Bioscience Holdings Limited shares rose about 8.5% to $44.96 in midday trading on Friday, clawing back from an early dip. The stock has swung between $35.13 and $50.92 in the session, with more than 1.1 million shares traded.
The bounce keeps attention on RGC after a stretch of sharp moves that has been hard to pin on fresh company updates. Regencell’s investor-relations site shows its most recent press release was dated Oct. 31. 1
Thursday was a reminder of how quickly the shares can turn: they ended down 21.7% at $41.42 after ranging from $34 to $69 on about 3.35 million shares, according to market data. Nasdaq halt records show the stock was paused twice on Thursday morning under the limit up-limit down code, at 10:16 a.m. and 10:29 a.m. ET. 2
Limit up-limit down, or LULD, is a market-wide volatility guardrail. It can pause trading if prices move outside preset bands around a rolling reference price. 3
Separately, Bragar Eagel & Squire said on Thursday it was investigating Regencell on behalf of stockholders. The firm asked investors who suffered losses to contact it. 4
Regencell has also been turning up on premarket movers lists as the volatility spilled into early trading. Barron’s flagged the shares up 13.5% before the open on Thursday. 5
But the company is still an early-stage operation focused on developing and commercializing traditional Chinese medicine for ADHD and autism spectrum disorder, its latest annual report said. The same filing shows CEO Yat-Gai Au controls about 88.6% of the shares, a structure that can magnify price swings when trading gets crowded. 6
Next up, traders are watching whether the stock can hold around Thursday’s closing level near $41. Broader risk assets face a new inflation test on Tuesday, when the Labor Department is due to release December CPI data at 8:30 a.m. ET. 7
